132 related articles for article (PubMed ID: 37119973)
1. Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors.
Hu Z; Sitkoff D; Glunz PW; Zou Y; Wang C; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2023 May; 88():129304. PubMed ID: 37119973
[TBL] [Abstract][Full Text] [Related]
2. Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors.
Pan J; Yin Y; Zhao L; Feng Y
Bioorg Med Chem; 2019 Apr; 27(7):1382-1390. PubMed ID: 30819619
[TBL] [Abstract][Full Text] [Related]
3. The selectivity and promiscuity of brain-neuroregenerative inhibitors between ROCK1 and ROCK2 isoforms: An integration of SB-QSSR modelling, QM/MM analysis and in vitro kinase assay.
Zhu L; Yang Y; Lu X
SAR QSAR Environ Res; 2016; 27(1):47-65. PubMed ID: 26854727
[TBL] [Abstract][Full Text] [Related]
4. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies.
Hu Z; Wang C; Glunz PW; Li J; Cheadle NL; Chen AY; Chen XQ; Myers JE; Guarino VR; Rose A; Sack JS; Sitkoff D; Taylor DS; Xu S; Yan C; Zhang H; Zhang L; Hennan J; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127495. PubMed ID: 32798651
[TBL] [Abstract][Full Text] [Related]
6. The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis.
Knipe RS; Probst CK; Lagares D; Franklin A; Spinney JJ; Brazee PL; Grasberger P; Zhang L; Black KE; Sakai N; Shea BS; Liao JK; Medoff BD; Tager AM
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):471-481. PubMed ID: 29211497
[TBL] [Abstract][Full Text] [Related]
7. Distinct Roles For ROCK1 and ROCK2 in the Regulation of Oxldl-Mediated Endothelial Dysfunction.
Huang L; Dai F; Tang L; Bao X; Liu Z; Huang C; Zhang T; Yao W
Cell Physiol Biochem; 2018; 49(2):565-577. PubMed ID: 30165352
[TBL] [Abstract][Full Text] [Related]
8. Discovery of unglycosylated indolocarbazoles as ROCK2 isoform-selective inhibitors for the treatment of breast cancer metastasis.
Wang J; Gao T; Ma Y; Zhang Y; Yi Y; Yan F; Cheng Z; Yu Y; Li J; Chen Z; Ding W; Ma Z
Eur J Med Chem; 2023 Mar; 250():115181. PubMed ID: 36764122
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors.
Wang L; Qi J; Fan M; Yao L
Chem Biol Drug Des; 2021 Dec; 98(6):969-978. PubMed ID: 34581498
[TBL] [Abstract][Full Text] [Related]
10. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
Hobson AD; Judge RA; Aguirre AL; Brown BS; Cui Y; Ding P; Dominguez E; DiGiammarino E; Egan DA; Freiberg GM; Gopalakrishnan SM; Harris CM; Honore MP; Kage KL; Kapecki NJ; Ling C; Ma J; Mack H; Mamo M; Maurus S; McRae B; Moore NS; Mueller BK; Mueller R; Namovic MT; Patel K; Pratt SD; Putman CB; Queeney KL; Sarris KK; Schaffter LM; Stoll V; Vasudevan A; Wang L; Wang L; Wirthl W; Yach K
J Med Chem; 2018 Dec; 61(24):11074-11100. PubMed ID: 30384606
[TBL] [Abstract][Full Text] [Related]
11. Distinct and complementary functions of rho kinase isoforms ROCK1 and ROCK2 in prefrontal cortex structural plasticity.
Greathouse KM; Boros BD; Deslauriers JF; Henderson BW; Curtis KA; Gentry EG; Herskowitz JH
Brain Struct Funct; 2018 Dec; 223(9):4227-4241. PubMed ID: 30196430
[TBL] [Abstract][Full Text] [Related]
12. Activation of Rho kinase isoforms in lung endothelial cells during inflammation.
Mong PY; Wang Q
J Immunol; 2009 Feb; 182(4):2385-94. PubMed ID: 19201893
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
[TBL] [Abstract][Full Text] [Related]
14. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
Patel RA; Forinash KD; Pireddu R; Sun Y; Sun N; Martin MP; Schönbrunn E; Lawrence NJ; Sebti SM
Cancer Res; 2012 Oct; 72(19):5025-34. PubMed ID: 22846914
[TBL] [Abstract][Full Text] [Related]
15. Vascular Stiffening Mediated by Rho-Associated Coiled-Coil Containing Kinase Isoforms.
Li Y; Tai HC; Sladojevic N; Kim HH; Liao JK
J Am Heart Assoc; 2021 Oct; 10(20):e022568. PubMed ID: 34612053
[TBL] [Abstract][Full Text] [Related]
16. Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy.
Pinca RS; Manara MC; Chiadini V; Picci P; Zucchini C; Scotlandi K
Oncol Rep; 2017 Mar; 37(3):1387-1393. PubMed ID: 28112365
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations.
Mei D; Yin Y; Wu F; Cui J; Zhou H; Sun G; Jiang Y; Feng Y
Bioorg Med Chem; 2015 May; 23(10):2505-17. PubMed ID: 25882521
[TBL] [Abstract][Full Text] [Related]
18. Rho-associated protein kinase isoforms stimulate proliferation of vascular smooth muscle cells through ERK and induction of cyclin D1 and PCNA.
Zhao Y; Lv M; Lin H; Cui Y; Wei X; Qin Y; Kohama K; Gao Y
Biochem Biophys Res Commun; 2013 Mar; 432(3):488-93. PubMed ID: 23402758
[TBL] [Abstract][Full Text] [Related]
19. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.
Li R; Martin MP; Liu Y; Wang B; Patel RA; Zhu JY; Sun N; Pireddu R; Lawrence NJ; Li J; Haura EB; Sung SS; Guida WC; Schonbrunn E; Sebti SM
J Med Chem; 2012 Mar; 55(5):2474-8. PubMed ID: 22272748
[TBL] [Abstract][Full Text] [Related]
20. Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
Uvin P; Albersen M; Bollen I; Falter M; Weyne E; Linsen L; Tinel H; Sandner P; Bivalacqua TJ; De Ridder DJ; Van der Aa F; Brône B; Van Renterghem K
BJU Int; 2017 Feb; 119(2):325-332. PubMed ID: 27763717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
